Fig. 2
Kaplan–Meier curves of (A) overall survival and (B) progression-free survival in patients in the SBRT and LEN groups after propensity score matching. LEN, lenvatinib; SBRT, Stereotactic Body Radiotherapy; CI, confident interval
Fig. 2 | Radiation Oncology